Liontrust Investment Partners LLP Sells 42,044 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

Liontrust Investment Partners LLP decreased its stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 7.0% in the first quarter, Holdings Channel.com reports. The fund owned 554,357 shares of the company’s stock after selling 42,044 shares during the period. Liontrust Investment Partners LLP’s holdings in TransMedics Group were worth $37,297,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of TMDX. NBC Securities Inc. bought a new position in shares of TransMedics Group during the first quarter worth $25,000. Hager Investment Management Services LLC lifted its position in TransMedics Group by 38.3% during the first quarter. Hager Investment Management Services LLC now owns 740 shares of the company’s stock valued at $50,000 after purchasing an additional 205 shares during the last quarter. CWM LLC lifted its position in TransMedics Group by 20.1% during the first quarter. CWM LLC now owns 925 shares of the company’s stock valued at $62,000 after purchasing an additional 155 shares during the last quarter. GAMMA Investing LLC lifted its position in TransMedics Group by 551.7% during the first quarter. GAMMA Investing LLC now owns 1,564 shares of the company’s stock valued at $105,000 after purchasing an additional 1,324 shares during the last quarter. Finally, Sava Infond d.o.o. lifted its position in TransMedics Group by 46.7% during the first quarter. Sava Infond d.o.o. now owns 2,200 shares of the company’s stock valued at $148,000 after purchasing an additional 700 shares during the last quarter. Institutional investors own 99.67% of the company’s stock.

TransMedics Group Trading Down 1.7%

TMDX stock opened at $129.74 on Friday. The company has a market capitalization of $4.42 billion, a PE ratio of 67.22 and a beta of 2.09. TransMedics Group, Inc. has a 12 month low of $55.00 and a 12 month high of $177.37. The firm’s 50-day moving average is $123.89 and its 200 day moving average is $99.05. The company has a debt-to-equity ratio of 1.61, a current ratio of 9.86 and a quick ratio of 9.17.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings results on Wednesday, July 30th. The company reported $0.92 EPS for the quarter, topping the consensus estimate of $0.48 by $0.44. The company had revenue of $157.37 million for the quarter, compared to the consensus estimate of $146.64 million. TransMedics Group had a net margin of 13.49% and a return on equity of 28.02%. The firm’s revenue was up 37.7% compared to the same quarter last year. During the same quarter last year, the firm posted $0.35 EPS. On average, research analysts anticipate that TransMedics Group, Inc. will post 1 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. Morgan Stanley increased their price objective on shares of TransMedics Group from $115.00 to $123.00 and gave the company an “equal weight” rating in a research report on Friday, August 1st. Wall Street Zen upgraded shares of TransMedics Group from a “hold” rating to a “buy” rating in a research report on Saturday, August 2nd. Canaccord Genuity Group increased their price objective on shares of TransMedics Group from $129.00 to $142.00 and gave the company a “buy” rating in a research report on Tuesday, July 15th. Piper Sandler reiterated an “overweight” rating and set a $145.00 price objective (up previously from $125.00) on shares of TransMedics Group in a research report on Wednesday, June 4th. Finally, Needham & Company LLC restated a “hold” rating on shares of TransMedics Group in a report on Tuesday, June 17th. Three investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $123.00.

Insider Buying and Selling

In other TransMedics Group news, insider Anil P. Ranganath sold 686 shares of the firm’s stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $139.80, for a total transaction of $95,902.80. Following the transaction, the insider owned 13,955 shares of the company’s stock, valued at approximately $1,950,909. This trade represents a 4.69% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Edward M. Basile sold 5,000 shares of the firm’s stock in a transaction dated Tuesday, May 27th. The shares were sold at an average price of $126.45, for a total transaction of $632,250.00. Following the transaction, the director directly owned 2,866 shares in the company, valued at $362,405.70. This trade represents a 63.56% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 6,418 shares of company stock valued at $818,833 in the last 90 days. Company insiders own 7.00% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.